Search results for "Immunological"

showing 10 items of 115 documents

Exposure to UV radiation and risk of Hodgkin lymphoma: A pooled analysis

2013

Ultraviolet radiation (UVR) exposure has been inversely associated with Hodgkin lymphoma (HL) risk, but only inconsistently, only in a few studies, and without attention to HL heterogeneity. We conducted a pooled analysis of HL risk focusing on type and timing of UVR exposure and on disease subtypes by age, histology, and tumor-cell Epstein-Barr virus (EBV) status. Four case-control studies contributed 1320HLcasesand 6381 controls. We estimated lifetime, adulthood, and childhood UVR exposure and history of sunburn and sunlamp use. We used 2-stage estimation with mixed-effects models and weighted pooled effect estimates by inverse marginal variances. We observed statistically significant inv…

OncologyMaleEpstein-Barr Virus InfectionsDNA RepairSunburnSkin PigmentationComorbidityBiochemistryT-Lymphocytes Regulatoryvisual_art.visual_artistimmune system diseaseshemic and lymphatic diseasesYoung adultSunburnAged 80 and overLymphoid NeoplasiaSunbathingintegumentary systemExposure CategoryInside BLOODConfoundingAge FactorsConfounding Factors EpidemiologicHematologyMiddle AgedHodgkin DiseaseEuropeHodgkin lymphoma (HL)visual_artSunlightFemaleAdultmedicine.medical_specialtyAdolescentUltraviolet RaysImmunologyBiologyWhite PeopleYoung AdultSunbathingInternal medicinemedicineHumansUltraviolet radiation (UVR)tumor-cell Epstein-Barr virus (EBV)AgedfungiCase-control studyModels ImmunologicalDose-Response Relationship RadiationCell BiologyOdds ratiomedicine.diseaseRelative riskCase-Control StudiesImmunologyDNA Damage
researchProduct

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).

2019

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1 (PD-L1) antibodies, showing, in several cancer patients, an increased progression-free survival and overall survival compared with classical chemotherapy. As recently shown by several studies, the PD-L1 expression levels in tumors may offer a selection criterion for patients to predict their immunotherapy response. In particular, NSCLC patients with high tumor PD-L1 levels (proportional score ≥ …

OncologyMalePD-L1030213 general clinical medicinemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesProgrammed Cell Death 1 Receptornon-small cell lung cancer (NSCLC)PembrolizumabReviewAntibodies Monoclonal HumanizedNSCLCB7-H1 Antigen03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalCheckpoint inhibitorPD-L1Internal medicineCarcinoma Non-Small-Cell LungPD-1medicineHumansPharmacology (medical)Molecular Targeted TherapyLung cancerNeoplasm StagingChemotherapybiologybusiness.industryCancerGeneral MedicineImmunotherapymedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisPredictive biomarker030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Lung cancerbusinessPembrolizumabBiomarkersCheckpoint inhibitorsAdvances in therapy
researchProduct

Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.

2020

Nivolumab is an anti&ndash

OncologyMalemedicine.medical_specialtymedicine.medical_treatmentT cellelderly patients03 medical and health sciences0302 clinical medicineImmune systemmelanoma metastaticAntineoplastic Agents ImmunologicalInternal medicinemedicineHumans030212 general & internal medicineNeoplasm MetastasisMelanomaAgedbiologybusiness.industryMelanomaclinical benefitlactate dehydrogenaseImmunotherapymedicine.diseaseConfidence intervalelderly patientmedicine.anatomical_structureNivolumabTolerability030220 oncology & carcinogenesisbiology.proteinQuality of LifeFemaleOriginal ArticleImmunotherapyNivolumabAntibodybusinessCurrent oncology (Toronto, Ont.)
researchProduct

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

2019

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Methods The ShortHER trial randomized 1253 HER2-positive patients to 9 weeks or 1 year of adjuvant trastuzumab combined with chemotherapy. Patients were classified according to the anatomic and the prognostic stage. Distant disease-free survival (DDFS) was calculated from randomization to distant relapse or death. Results A total of 1244 patients were included. Compared to anatomic stage, the prognost…

OncologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentlcsh:MedicineAntineoplastic Agents Immunological0302 clinical medicineBreast cancerTrastuzumabAntineoplastic Combined Chemotherapy Protocols8th AJCC030212 general & internal medicineStage (cooking)8th AJCC; Breast cancer; HER2-positive; Prognostic stage; TrastuzumabGeneral MedicineMiddle AgedPrognosisImmunologicalLocal030220 oncology & carcinogenesisFemaleResearch Articlemedicine.drugAdultmedicine.medical_specialtyRandomizationSocio-culturaleAntineoplastic AgentsBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancerInternal medicinePrognostic stagemedicineAdjuvant therapyHumanserbB-2AgedNeoplasm StagingCancer stagingChemotherapybusiness.industrylcsh:RCancerGenes erbB-2Trastuzumabmedicine.diseaseHER2-positive Breast cancer Trastuzumab Prognostic stage 8th AJCCHER2-positiveNeoplasm RecurrenceGenesNeoplasm Recurrence Localbusiness
researchProduct

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

2018

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…

OncologyTime FactorsAdjuvant Breast cancer Cardiac safety De-escalated treatment TrastuzumabSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentAnthracycline030204 cardiovascular system & hematologyBreast cancerAntineoplastic Agents ImmunologicalErbB-20302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsClinical endpointAnthracyclinesskin and connective tissue diseasesAdjuvantMastectomyAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab;Hazard ratioHematologyMiddle AgedChemotherapy regimenBridged-Ring CompoundImmunologicalLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleTaxoidsTrastuzumab adjuvant breast cancer cardiac safety de-escalated treatmentBreast NeoplasmMastectomyHumanReceptormedicine.drugAdultBridged-Ring Compoundsmedicine.medical_specialtyTime FactorSocio-culturaleBreast NeoplasmsAntineoplastic AgentsDe-escalated treatmentDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerTaxoidInternal medicinemedicineHumansChemotherapyRisk factorAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy ProtocolCardiac safetybusiness.industryTrastuzumabAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab; Hematology; Oncologymedicine.diseaseCardiotoxicityNeoplasm RecurrenceNeoplasm Recurrence LocalbusinessAnnals of Oncology
researchProduct

French Endocrine Society Guidance on endocrine side effects of immunotherapy.

2018

The management of cancer patients has changed due to the considerably more frequent use of immune checkpoint inhibitors (ICPIs). However, the use of ICPI has a risk of side effects, particularly endocrine toxicity. Since the indications for ICPI are constantly expanding due to their efficacy, it is important that endocrinologists and oncologists know how to look for this type of toxicity and how to treat it when it arises. In view of this, the French Endocrine Society initiated the formulation of a consensus document on ICPI-related endocrine toxicity. In this paper, we will introduce data on the general pathophysiology of endocrine toxicity, and we will then outline expert opinion focusing…

PD-L1Cancer Researchmedicine.medical_specialtyHypophysitisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmune checkpoint inhibitorsimmune checkpoint inhibitorEndocrine System DiseasesGuidelines and GuidanceEndocrinologyAntineoplastic Agents ImmunologicalPD-1medicineAdrenal insufficiencyEndocrine systemHumansIn patientthyrotoxicosisIntensive care medicinediabetesbusiness.industryCommon Terminology Criteria for Adverse EventsImmunotherapymedicine.diseaseFrequent usehypophysitisOncologyCTLA-4FranceImmunotherapyhypothyroidismbusinessadrenal insufficiencyEndocrine-related cancer
researchProduct

A potential role of interferon-gamma in the pathogenesis of venous leg ulcers.

2005

Venous leg ulcer is the most severe expression of chronic venous insufficiency. Venous ulcerations are always associated with venous ambulatory hypertension, but the exact mechanism leading from pathological hemodynamics in venous circulation to the necrotic lesions in the skin still remains undiscovered. It has been shown that tissue injury in venous ulcer patients was induced by leukocytes. However, though infiltrating leukocytes have at their disposal a powerfully cytotoxic arsenal, it has not been discovered which molecular mechanisms may contribute to the skin damage. The search for this hypothetical factor responsible for the development of ulceration should be focused on mechanisms l…

Pathologymedicine.medical_specialtyNecrosisChronic venous insufficiencybusiness.industrymedicine.medical_treatmentLeg UlcerModels ImmunologicalGeneral Medicinemedicine.diseaseVenous leg ulcerPathophysiologyProinflammatory cytokineVaricose UlcerPathogenesisInterferon-gammaCytokinemedicineHumansmedicine.symptombusinessLeukocyte chemotaxisMedical hypotheses
researchProduct

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

2016

Melanoma treatment has been revolutionized by antibody-based immunotherapies. IFNγ secretion by CD8+ T cells is critical for therapy efficacy having anti-proliferative and pro-apoptotic effects on tumour cells. Our study demonstrates a genetic evolution of IFNγ resistance in different melanoma patient models. Chromosomal alterations and subsequent inactivating mutations in genes of the IFNγ signalling cascade, most often JAK1 or JAK2, protect melanoma cells from anti-tumour IFNγ activity. JAK1/2 mutants further evolve into T-cell-resistant HLA class I-negative lesions with genes involved in antigen presentation silenced and no longer inducible by IFNγ. Allelic JAK1/2 losses predisposing to …

Patient-Specific Modeling0301 basic medicineSkin NeoplasmsBiopsyT-LymphocytesDNA Mutational AnalysisDatasets as TopicGeneral Physics and AstronomyAntineoplastic Agents ImmunologicalMutation RatePrecision MedicineMelanomaSkinAntigen PresentationMultidisciplinarybiologyMelanomaQfood and beverages3. Good healthTreatment Outcomemedicine.anatomical_structureImmunotherapyAntibodySignal TransductionScienceT cellAntigen presentationHuman leukocyte antigenArticleGeneral Biochemistry Genetics and Molecular BiologyInterferon-gamma03 medical and health sciencesAntigenAntigens NeoplasmCell Line TumormedicineHumansWhole Genome SequencingHistocompatibility Antigens Class IJanus Kinase 1General ChemistryJanus Kinase 2medicine.disease030104 developmental biologyImmunoeditingDrug Resistance NeoplasmMutationImmunologybiology.proteinTumor EscapeCD8Nature Communications
researchProduct

Cellular effects of bacterial N-3-Oxo-dodecanoyl-L-Homoserine lactone on the sponge Suberites domuncula (Olivi, 1792): insights into an intimate inte…

2014

International audience; Sponges and bacteria have lived together in complex consortia for 700 million years. As filter feeders, sponges prey on bacteria. Nevertheless, some bacteria are associated with sponges in symbiotic relationships. To enable this association, sponges and bacteria are likely to have developed molecular communication systems. These may include molecules such as N-acyl-L-homoserine lactones, produced by Gram-negative bacteria also within sponges. In this study, we examined the role of N-3-oxododecanoyl-L-homoserine lactone (3-oxo-C12-HSL) on the expression of immune and apoptotic genes of the host sponge Suberites domuncula. This molecule seemed to inhibit the sponge inn…

ProteomicsApoptosisPathogenesisPathology and Laboratory MedicineBiochemistrycaspase 74-Butyrolactonecaspase 3lcsh:ScienceCytoskeletoncaspase like 7 gene0303 health sciencesToll-like receptorMarine Ecologytoll like receptorGenomicsproto oncogeneEndocytosisCell biologySuberites domunculaCellular Structures and Organellesalpha actininCell signalingtoll like receptor associated factor 6Gram negative bacteriumparacrine signalingMicrobiology03 medical and health sciencesGeneticsRNA Messengerhost pathogen interactionprotein expressiontwo dimensional electrophoresisBacteria030306 microbiologyEcology and Environmental Scienceslcsh:RBiology and Life SciencesComputational BiologyImmunity Innatecarrier proteinSpongebacterial membranelcsh:Qimmunological toleranceSuberitesProtein AbundanceSuberitessuberites domuncula[SDV]Life Sciences [q-bio]lcsh:MedicineMolecular Cell BiologyMedicine and Health Sciencesinnate immunityperforinMultidisciplinaryEcologybiologymessenger RNAarticlecell communicationAnimal Modelsmatrix assisted laser desorption ionization time of flight mass spectrometryunclassified drugPoriferaHost-Pathogen InteractionscytotoxicityactinTranscriptome Analysishormone actionResearch ArticleSymbiotic bacteriaprotein bcl 2Marine BiologycofilinResearch and Analysis Methodsn (3 oxododecanoyl)homoserine lactoneMicrobial EcologycogninModel OrganismsHomoserineAnimalscontrolled study14. Life underwatergeneSymbiosiscell viabilityadenosine triphosphatase030304 developmental biologynonhumanChemical EcologyMembrane ProteinsCell Biologytumor necrosis factor receptor associated factor 6Genome Analysisbiology.organism_classificationalpha tubulinGene Expression RegulationMembrane proteingene expressioncaspase like 3 geneGenome Expression AnalysisBacteriaPLoS ONE
researchProduct

Epithelial-mesenchymal communication in the pathogenesis of chronic asthma.

2005

Although Th-2-mediated inflammation is a key therapeutic target in asthma, its relationship to altered structure and functions of the airways is largely unknown. In addition to inflammation, asthma is a disorder involving the airway epithelium that is more vulnerable to environmental injury and responds to this by impaired healing. This establishes a chronic wound scenario that is capable of sustaining chronic inflammation as well as remodeling. This response occurs as a consequence of activation of the epithelial-mesenchymal unit, involving reciprocal activities of growth factors belonging to the fibroblast growth factor, epidermal growth factor, and transforming growth factor-beta familie…

Pulmonary and Respiratory MedicineChronic woundInflammationBiologyFibroblast growth factorPathogenesisTh2 CellsEpidermal growth factormedicineHumansGrowth Substancesasthma InflammationAsthmaInflammationWound HealingMesenchymal stem cellModels ImmunologicalEpithelial CellsMuscle SmoothFibroblastsmedicine.diseaseAsthmarespiratory tract diseasesImmunologyChronic DiseaseRespiratory Physiological PhenomenaRespiratory epitheliumCytokinesmedicine.symptom
researchProduct